Finding. Bone talks to the spinal cord. Romeo Guitart, Karsenty, Oury and colleagues show that osteocalcin, the osteoblast hormone, lands on GPR158 in spinal cholinergic motoneurons and keeps autophagy, mitophagy, and mitochondrial activity in a workable band. Delete GPR158 in the whole mouse or only in those motoneurons, or delete osteocalcin itself, and walking fails while choline acetyltransferase falls. Force mitophagy with a drug, or turn mitochondria back on with a chemogenetic actuator, and the Gpr158-deficient mice locomote again. Give osteocalcin back to old mice and age-related motor decline reverses, but only if motoneuron autophagy and mitophagy are still there to receive the signal.
Why this paper matters
Motoneuron disease and ordinary aging are usually narrated as irretrievable cell loss. This preprint argues a different layer: the skeleton is an endocrine support system for motoneuron mitochondria, and some of the motor phenotype is a maintenance failure you can still reverse. That is a bigger sentence than "osteocalcin affects muscle." The receptor is on the motoneuron. The rescue is mitochondrial. The aged-mouse experiment says the decline is not finished business.
It also gives body-brain communication a concrete circulating ligand. Spinal motoneurons already wear hormone receptors. The open question in the abstract is whether a peripheral organ uses those receptors to report energetic state. Bone, via osteocalcin and GPR158, is their answer.
What they actually measured
GPR158 is selectively enriched in spinal cholinergic motoneurons, which is why a global knockout and a motoneuron-specific knockout can tell the same story. Locomotor impairment tracks reduced ChAT, the enzyme that stamps cholinergic identity. Mechanistically the authors place OCN-GPR158 on three linked processes: autophagy, mitophagy, and mitochondrial activity. The genetic logic is completed by rescue: restoring any one of those processes is enough to fix walking in Gpr158-deficient mice. The aging arm is the one non-geneticists will quote. Osteocalcin restoration reverses locomotor decline in old mice through a pathway that still needs motoneuron autophagy and mitophagy. Hormone without organelle quality control does not work.
How to read the score
Low 90s. Primary mitochondrial mechanism in a disease-relevant cell, genetic necessity, cell-type restriction, and two styles of rescue plus an aging reversal. Confidence is high for the mouse circuit. It is not high for a human therapeutic dose or for amyotrophic lateral sclerosis.
Caveats
This brief is abstract-level. The mitophagy drug and the chemogenetic tool are not named here. Reversible locomotor decline is not regeneration of dead motoneurons. Osteocalcin has a long, contested metabolic literature; this paper should be read as a motoneuron-mitochondria study, not as a settlement of that older fight.
What to do with it
If you model motoneuron aging, neuromuscular junction failure, or mitophagy in cholinergic neurons, this is the week's endocrine paper. Pull GPR158 expression, the ChAT drop, and the aged-mouse requirement for autophagy/mitophagy. Do not write a clinical osteocalcin protocol from this brief. Do write the hypothesis that some late-life weakness is a bone-to-mitochondria signal going quiet.